OOIR: Observatory of International Research

Papers

(The median citation count of Multiple Sclerosis Journal is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Time to move past typical syndromes in the diagnosis of multiple sclerosis	69
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary	68
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary	67
Therapy challenges for NMOSD in a patient with HIV	57
Reply to letter to the editor: Olfactory threshold as a biomarker of disease activity	57
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient	55
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Yes	54
Sars-CoV2 infection in pregnant women with multiple sclerosis	54
Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No	54
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO	48
Thematic analysis of multiple sclerosis research by enhanced strategic diagram	44
Progression independent of relapse activity in multiple sclerosis: Time to account for cognitive decline	43
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series	40
Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis	40
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study	39
Paramagnetic rim lesions predict greater long-term relapse rates and clinical progression over 10 years	37
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity	34
GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis	34
Decentralised clinical trials in multiple sclerosis research	33
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions	33
An interdisciplinary approach is necessary in the treatment of cognitive decline in MS: No	32
Double-negative neuromyelitis optica spectrum disorder	31
Erratum to “Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis” Multiple Sclerosis Journal; 2024: 30(8); 1086–1088. DOI: 10.1177/13524585241260564.	30
Productivity loss among people with early multiple sclerosis: A Canadian study	30
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study	29

The MoXFo initiative – study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis	29
Cerebrospinal fluid–related tissue damage in multiple sclerosis patients with iron rim lesions	29
To halt disease progression rehabilitation in MS should start early: Yes	28
The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years—Protocol, recruitment status, and baseline characteristics	27
Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis	27
A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma	27
Assessing diagnosis disclosure and concealment in multiple sclerosis: Development and initial validation of the DISCO-MS survey	26
No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry	26
Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary	26
Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study	26
Anti-CD20 therapy in pregnancy: Balancing risks and benefits	25
Pseudocystic demyelination in multiple sclerosis	25
Low-dose rituximab should be used for treating MS in resource-limited settings: No	25
Long-term modifications of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in multiple sclerosis	24
The value of patient-reported outcome measures for multiple sclerosis	24
Aspergillus myelitis: Breaking the mold to make a diagnosis	23
Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary	23
Low transfer of cladribine into human milk	23
Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis	22
The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022	22
White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study	22
Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study	21
Biological aging in multiple sclerosis	21
Is there a prodrome to NMOSD? An investigation of neurologic symptoms preceding the first NMOSD attack	21
Metabolic and lipid alterations in multiple sclerosis linked to disease severity	21
Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis	20
Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients	20
Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial	20
Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review	20
Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation	20
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society	20
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial	19
The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis	19
Understanding who benefits most from cognitive rehabilitation for multiple sclerosis: A secondary data analysis	19
Ofatumumab-associated colitis: A case report	19
Longitudinal enlargement of choroid plexus is associated with chronic lesion expansion and neurodegeneration in RRMS patients	19
EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold	19
Depression is a core symptom of multiple sclerosis: Yes	19
International Multiple Sclerosis Cognition Society Meeting Bordeaux, France, May 18-19 2022	18
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort	18
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France	18
Frailty in multiple sclerosis: A closer look at the deficit accumulation framework	18
Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community	18
DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity – Commentary	18
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study	17
Mobile health interventions in multiple sclerosis: A systematic review	17
The effects of gamma-tACS on cognitive impairment in multiple sclerosis: A randomized, double-blind, sham-controlled, pilot study	17
Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: YES	17
What is a clinically isolated syndrome in the 21st century?	17
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor	17

Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis	17
Response to the letter: Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model	17
Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? No	17
High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate	17
Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis	17
Longitudinal investigation of neuroimaging changes related to memory decline in multiple sclerosis: Testing a mechanistic model	17
Deep gray matter substructure volumes and depressive symptoms in a large multiple sclerosis cohort	16
The MoXFo initiative – adherence: Exercise adherence, compliance and sustainability among people with multiple sclerosis: An overview and roadmap for research	16
Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome	16
Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis	15
Exercise as a Therapeutic Intervention in Multiple Sclerosis	15
Addressing me in the context of my disease: Why it is so complicated	15
Disentangling multiple sclerosis phenotypes through Mendelian disorders: A network approach	15
Prediction of multiple sclerosis outcomes when switching to ocrelizumab	15
Towards a phenotypic understanding of multiple sclerosis depression	15
Telomere length as a biomarker in multiple sclerosis	15
Olfactory threshold predicts treatment response in relapsing multiple sclerosis	15
Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model	15
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study	15
Epilepsy as a predictor of disease progression in multiple sclerosis	15
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy	15
Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort	15
Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis	15
Discrepancies in the results reported for multiple sclerosis clinical trials: A comparison between ClinicalTrials.gov and peer-reviewed journals	14
Machine learning classification of multiple sclerosis in children using optical coherence tomography	14
Gene–environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution	14
Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis	14
Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden	14
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement	14
Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis	14
New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series	14
Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021	14
Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations	14
A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort stu	14
Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis	13
Baló’s concentric sclerosis successfully treated with alemtuzumab: Long-term follow-up	13
Clinical and radiologic characteristics associated with multiple sclerosis misdiagnosis at a tertiary referral center in the United States	13
Racial and Ethnic Disease Phenotype Differences Are Driven by Genetics - Yes	13
Copy number variation at the complement C4 locus is associated with risk for multiple sclerosis	13
Corpus callosum damage to account for cognitive, affective, and social-cognitive dysfunctions in multiple sclerosis: A model of callosal disconnection syndrome?	13
Prevalence of neuromyelitis optica spectrum disorder in the United States	13
Acute retinal necrosis associated with dimethyl fumarate	13
ECTRIMS 2021 - Author Index	13
Navigating the uncharted—Progressive multifocal leukoencephalopathy in a child with NMOSD treated with rituximab	13
Cognitive reserve in multiple sclerosis: The role of depression and fatigue	13
Response to letter to the editor: ‘Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis’	13
Clinical correlates of respiratory disorders in patients with severe multiple sclerosis: A cross-sectional cohort	13
Exosomal profiling should be used to monitor disease activity in MS patients: Commentary	12
Response to letter to the editor “Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs”	12
Aquaporin-4 antibody neuromyelitis optica spectrum disorder: A paraneoplastic disease?	12
All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes	12
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica	12
Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study	12
Assessing the association between mortality and clinical follow-up visits in multiple sclerosis	12
ACTRIMS Forum 2023 Invited Program	12
Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis	12
From “invisible” to “audible”: Features extracted during simple speech tasks classify patient-reported fatigue in multiple sclerosis	12
Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO	12
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice	11
The Barancik award lecture: Multi-disciplinary research will be the key to stop, restore, and end MS	11
Cladribine and pregnancy in women with multiple sclerosis: The first cohort study	11
External validation of a clinical prediction model in multiple sclerosis	11
Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clini	11
The confavreux lecture: The radiologically isolated syndrome diagnosis, prognosis and perspectives	11
Extended dosing of monoclonal antibodies in multiple sclerosis	11
A taxonomic approach to cognitive diagnostics is viable and achievable in MS	11
ECTRIMS 2024 – Oral Presentations	11
Characteristics of multiple sclerosis and demyelinating disease in an Asian American population	11
ACTRIMS Forum 2023 - Poster Presentations	11
Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data	11
Differential vulnerability of thalamic nuclei in multiple sclerosis	11
Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis	11
ACTRIMS Forum 2025 Author Index	11
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study	10
Neighborhood disadvantage, race, and clinical outcomes in neuromyelitis optica spectrum disorder	10
Response to “Frailty in multiple sclerosis: A closer look at the deficit accumulation framework”	10
Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC)	10
The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis	10
The MoXFo Initiative: Using consensus methodology to move forward towards internationally shared vocabulary in multiple sclerosis exercise research	10
Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome	10

Paramagnetic rim lesion formation is predicted by the initial gadolinium-enhancing lesion diameter	10
Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions	10
Homonymous hemi-macular atrophy in multiple sclerosis	10
Exosomal profiling should be used to monitor disease activity in MS patients: No	10
Persistent gadolinium enhancement: An emerging MRI feature in NMOSD?	10
Demyelinating disorders following COVID-19 vaccination	10
ECTRIMS 2021 Committees	10
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy)	10
The impact of social distancing measures on anti–JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis	10
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Commentary	10
Sleep-disordered breathing and neurocognitive function in multiple sclerosis: Differential associations across cognitive domains	10
Association between education level and disability progression in patients with multiple sclerosis in France	10
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial	10
MS becomes a treatable disease: 30 years later	10
Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study	10
Neurofilament light biomarkers in MS: Effects of extended natalizumab dosing	10
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions	10
Multiple Sclerosis Cognitive Scale (MSCS): A brief psychometrically robust metric of patient-reported cognitive difficulty	9
Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein–associated disease	9
ACTRIMS Forum 2023 Author Index	9
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS	9
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society	9
Unemployment, work hour reduction, and income loss: An international, multicentered, cross-sectional study of neuromyelitis optica spectrum disorder	9
Treating comorbidities in multiple sclerosis is disease modifying: Yes	9
Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss	9
Communication deficits in multiple sclerosis: Interactions with cognitive dysfunction and their impact on employment status	9
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial	9
Relapsing tumefactive demyelination: time to recognize a distinct demyelinating condition?	9
Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis	9
Mobility trajectories in multiple sclerosis: A comparative study of timed 25-foot walk and a patient-reported outcome measure	9
Anti-CGRP therapies for migraine in multiple sclerosis patients	9
Seizure history and cognitive dysfunction in people with multiple sclerosis	9
Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS	9
Employment status, productivity loss, and associated factors among people with multiple sclerosis	9
Slower retinal thinning over a year predicts continuous NEDA status at follow-up in multiple sclerosis: A longitudinal OCT study	9
Longitudinally extensive posterolateral myelitis revealing invasive CNS aspergillosis in an immunocompetent patient	9
Depression is a core symptom of multiple sclerosis: No	9
Phonemic processing is below expectations and linked to word-finding difficulty in multiple sclerosis	9
Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study	9
Treating comorbidities in MS is disease modifying: Commentary	9
Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease	9
Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis	9
Reduced childbirth rates in multiple sclerosis from the prodromal phase: Evidence from a population-based cohort study	8
The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions	8
Toward a holistic approach to multiple sclerosis: The role of social determinants of health	8
How to avoid missing a diagnosis of neuromyelitis optica spectrum disorder	8
Rectifying global inequities in neuromyelitis optica diagnosis and treatment	8
Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis?	8
Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: No	8
The characteristics and influencing factors of paramagnetic rim lesions in Chinese MS patients: A 7T MRI study	8
The time to include cognition in the multiple sclerosis concept of progression independent from relapse activity is now	8
Trends in central nervous system-active polypharmacy among people with multiple sclerosis	8
Generic MS medications: Reducing costs without compromising safety	8
A custom-built step exergame training programme to prevent falls in people with multiple sclerosis: A multicentre randomised controlled trial	8
Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse	8
Functional and structural MRI correlates of executive functions in multiple sclerosis	8
A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients	8
Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis	8
Facial pain in MS: When to think of trigeminal autonomic cephalalgia	8
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis	8
Hypnosis and mindfulness audio recordings for reducing fatigue in individuals with multiple sclerosis: A randomized controlled study	8
Committees	7
Navigating pregnancy in women with NMOSD in the monoclonal antibody era	7
Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis	7
Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study	7
Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis	7
Slowly expanding lesions are a marker of progressive MS – No	7
SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?	7
Psoriasisform dermatitis following anti-CD20 therapies: Immunologic lessons and management dilemmas	7
Response to—Tracking the role of sphingolipids in MS: The dynamic nature of ceramide synthases	7
Abstracts presented at the 10th Annual Meeting International MS Cognition Society (IMSCOGS), 2-3 September 2024, Bern, Switzerland	7
Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients	7
Therapy with mesenchymal stem cell transplantation in multiple sclerosis ready for prime time: Commentary	7
Multiple sclerosis can be diagnosed solely with dissemination in space: Yes	7
Severe coxsackie virus B5 encephalitis mimics autoimmune limbic encephalitis in a young woman under long-term B-cell depletion with ocrelizumab: A case report	7
Post-acute sequela of COVID-19 infection in individuals with multiple sclerosis	7
The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients – No	7
Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders	7
Vaccination as a risk factor for pediatric multiple sclerosis: Insights from a retrospective case–control study	7
Randomized Controlled Trials of Rehabilitation in Multiple Sclerosis: Barriers and Unmet Needs	7
Computational basis of decision-making impairment in multiple sclerosis	7
Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal	7
Recommendations for the use of propensity score methods in multiple sclerosis research	7
Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial	7
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial	7
Brain and cervical spinal cord MRI correlates of sensorimotor impairment in patients with multiple sclerosis	7
Blended versus face-to-face cognitive behavioural therapy for severe fatigue in patients with multiple sclerosis: A non-inferiority RCT	7
Delayed amantadine toxicity causing apparent progression of multiple sclerosis	6
Exploring the relationship between polycystic ovarian syndrome, testosterone, and multiple sclerosis in women: A nationwide cohort study and genome-wide cross-trait analysis	6
Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs	6
RIMS Digital Conference 2021	6
White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study	6
Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study	6
ECTRIMS 2024 – ePoster	6
Enhancing diversity of clinical trial populations in multiple sclerosis	6